Head-To-Head Contrast: Pharma Bio Serv (PBSV) & Lightbridge (LTBR)

Pharma Bio Serv (OTCMKTS:PBSV) and Lightbridge (NASDAQ:LTBR) are both small-cap business services companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Pharma Bio Serv and Lightbridge, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharma Bio Serv 0 0 0 0 N/A
Lightbridge 0 0 0 0 N/A

Insider and Institutional Ownership

6.3% of Lightbridge shares are held by institutional investors. 51.6% of Pharma Bio Serv shares are held by insiders. Comparatively, 11.6% of Lightbridge shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Pharma Bio Serv has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Lightbridge has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500.


This table compares Pharma Bio Serv and Lightbridge’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pharma Bio Serv 7.07% 7.61% 6.11%
Lightbridge N/A -65.44% -61.76%


Pharma Bio Serv pays an annual dividend of $0.08 per share and has a dividend yield of 7.1%. Lightbridge does not pay a dividend. Pharma Bio Serv pays out -133.3% of its earnings in the form of a dividend.

Earnings & Valuation

This table compares Pharma Bio Serv and Lightbridge’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pharma Bio Serv $17.79 million 1.47 $1.27 million ($0.06) -18.67
Lightbridge $170,000.00 107.64 -$7.10 million N/A N/A

Pharma Bio Serv has higher revenue and earnings than Lightbridge.


Pharma Bio Serv beats Lightbridge on 8 of the 11 factors compared between the two stocks.

About Pharma Bio Serv

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm the United States, Europe, and Brazil markets. It provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products in Puerto Rico, the United States, Europe, and Brazil. The company's technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.

About Lightbridge

Lightbridge Corporation operates as a nuclear fuel technology company worldwide. It operates through two segments, Technology and Consulting. It offers all-metal fuel for operating and new build reactors; all-uranium seed and blanket fuel for existing plants and new build reactors; and thorium-based seed and blanket fuel for existing and new build reactors. The company also provides nuclear power consulting and strategic advisory services to commercial and governmental entities. Its services include integrated strategic advice across a range of areas, including regulatory development, nuclear reactor site selection, procurement and deployment, reactor and fuel technology, international relations, program management, and infrastructure development. The company was formerly known as Thorium Power, Ltd. and changed its name to Lightbridge Corporation in September 2009. Lightbridge Corporation was founded in 1992 and is based in Reston, Virginia.

Receive News & Ratings for Pharma Bio Serv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Bio Serv and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit